{
  "docId": "019de071-b74f-770c-80cd-22f6f746fca1",
  "docSlug": "da6e8db4dad70fc7ff4e589a15b2ab41",
  "documentTitle": "BioNTech | Results Presentation Deck | 40 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 29,
  "pageCount": 40,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "Clinical trial data summary slide.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-b74f-770c-80cd-22f6f746fca1/29",
  "deckHref": "/decks/019de071-b74f-770c-80cd-22f6f746fca1",
  "deckJsonHref": "/decks/019de071-b74f-770c-80cd-22f6f746fca1.json",
  "deckAnchorHref": "/decks/019de071-b74f-770c-80cd-22f6f746fca1#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.28,
        "x": 0.68,
        "y": 0.3
      },
      "kind": "list",
      "text": "Increased levels of: Peripheral monocyte and DC cytokines (IFN-y, TARC); CD8+ total and effector memory T cells",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2f3f54cc-2277-4330-b9a5-772fbadbaaa7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.28,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "list",
      "text": "Median 57 years old; Most common cancer types: Colorectal (22%), Melanoma (20%), NSCLC (8%); Median of 2.5 treatment cycles; Cmax observed shortly after end of infusion",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5c0b1bdc-da54-432e-80fd-7035479ef81c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.28,
        "x": 0.68,
        "y": 0.5
      },
      "kind": "metric",
      "text": "51% of patients (n=25/49) achieved disease control",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0dfc275a-7034-48be-8e56-61214f6cd2db",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.92,
        "x": 0.04,
        "y": 0.84
      },
      "kind": "paragraph",
      "text": "Further Evaluation: 100 mg every 3 weeks was identified as the expansion dose",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dd6b6f46-8e97-4078-aa46-d3bda4d55766",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.75,
        "x": 0.07,
        "y": 0.935
      },
      "kind": "source-note",
      "text": "Data cutoff: 1 July 2021. Cmax: peak serum concentration; AE, adverse event; DC, dendritic cell; DLT, dose-limiting toxicity; IFN-y, interferon gamma; TARC, thymus- and activation-regulated chemokine; NSCLC: Non-small-cell lung cancer",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5d6b6b4b-2bb4-4d05-95cb-d69c1d7bf2dd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.35,
        "y": 0.38
      },
      "kind": "table",
      "text": "Fatigue 22% -; Pyrexia 16% -; Nausea 10% -; Transaminase elevation 10% 6%",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b448485a-7560-444c-90de-7ab18b9243d4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.92,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "SITC 2021 - BNT312 Phase 1/2: Favorable Safety Profile, Biologic Activity and Early Antitumor Activity Observed with Monotherapy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "27b2b165-4764-4bdf-8506-dc00c4378eb0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 40,
      "from": 21,
      "beatId": "86ee922b-3b38-407a-91d0-e5fba14e6389",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The presentation concludes with financial results, outlook, and future plans",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 30,
      "from": 21,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "8d1b4261-4f6e-4fae-a0eb-442f564dc509",
      "evidence": "The presentation mentions the potential to tackle multiple diseases with different therapeutic modalities",
      "position": 1,
      "objective": "To highlight the potential consequences of not addressing serious diseases",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}